Oramed Pharmaceuticals Ownership
| ORMP Stock | USD 2.34 0.03 1.30% |
Shares in Circulation | First Issued 2003-09-30 | Previous Quarter 40.6 M | Current Value 40.2 M | Avarage Shares Outstanding 14.6 M | Quarterly Volatility 12.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Oramed |
Oramed Stock Ownership Analysis
About 17.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.6. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oramed Pharmaceuticals had not issued any dividends in recent years. The entity had 1:12 split on the 23rd of January 2013. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York. Oramed Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. To find out more about Oramed Pharmaceuticals contact Nadav Esq at 844 967 2633 or learn more at https://www.oramed.com.Oramed Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oramed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oramed Pharmaceuticals backward and forwards among themselves. Oramed Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Oramed Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Squarepoint Ops Llc | 2024-06-30 | 81.8 K | State Street Corp | 2024-06-30 | 59.3 K | Jane Street Group Llc | 2024-06-30 | 56.1 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 48.8 K | Lpl Financial Corp | 2024-06-30 | 40.5 K | D. E. Shaw & Co Lp | 2024-06-30 | 38.6 K | Pnc Financial Services Group Inc | 2024-09-30 | 26.2 K | Wells Fargo & Co | 2024-06-30 | 25.6 K | Geode Capital Management, Llc | 2024-06-30 | 25.5 K | Bml Capital Management Llc | 2024-09-30 | 2.2 M | Murchinson Ltd. | 2024-06-30 | 1.7 M |
Oramed Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oramed Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oramed Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oramed Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oramed Pharmaceuticals' latest congressional trading
Congressional trading in companies like Oramed Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Oramed Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
| 2022-01-14 | Representative Andrew Garbarino | Acquired Under $15K | Verify |
Oramed Pharmaceuticals Outstanding Bonds
Oramed Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oramed Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oramed bonds can be classified according to their maturity, which is the date when Oramed Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US68404LAA08 Corp BondUS68404LAA08 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Oramed Pharmaceuticals Corporate Filings
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 16th of September 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Pair Trading with Oramed Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Oramed Stock
Moving against Oramed Stock
| 0.62 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.48 | GILD | Gilead Sciences | PairCorr |
| 0.47 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Oramed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oramed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oramed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oramed Pharmaceuticals to buy it.
The correlation of Oramed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oramed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oramed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oramed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.